Related Experiment Videos
Leucopenia caused by two rifampicin preparations.
European Journal of Respiratory Diseases
|May 1, 1984
Summary
Tuberculosis drug Rimapen caused significantly more leucopenia (low white blood cell count) than Rimactan. Doctors should monitor patients for this side effect and consider drug withdrawal.
Area of Science:
- Pharmacology
- Infectious Diseases
- Hematology
Background:
- Tuberculosis chemotherapy often involves rifampicin.
- Rifampicin is associated with potential adverse effects, including leucopenia.
- Different rifampicin preparations may have varying safety profiles.
Purpose of the Study:
- To compare the incidence of leucopenia caused by two different rifampicin preparations.
- To assess the safety profile of Rimapen versus Rimactan in tuberculosis treatment.
Main Methods:
- A comparative study involving two groups of tuberculosis patients.
- Group 1 (n=140) received Rimapen; Group 2 (n=132) received Rimactan.
- Leucopenia was defined as a leucocyte count of 3000 cells/microliter or less and monitored during daily chemotherapy.
Main Results:
- Eleven cases (7.9%) of leucopenia were observed in the Rimapen group.
- One case (0.8%) of leucopenia occurred in the Rimactan group.
- The difference in leucopenia incidence between the two preparations was statistically significant (p < 0.01).
Conclusions:
- Rimapen is associated with a significantly higher frequency of leucopenia compared to Rimactan.
- The incidence of leucopenia with Rimapen is notably higher than previously reported.
- Management of rifampicin-induced leucopenia includes drug withdrawal or careful monitoring; re-initiation after a pause is generally not recommended.